Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Vomiting was reported by 24% of the patients, diarrhea by 30%, constipation 24%, abdominal pain 20%, headache 14%, fatigue (tiredness) 11%, indigestion 9%, dizziness 8%, abdominal bloating 7%, flatulence 6%, loud burping 7%, low blood sugar (hypoglycemia) 6% and other side effects
Currently, the only oral GLP-1 approved for diabetes remains Rybelsus (oral semaglutide by Novo Nordisk)
Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing
A brand name does not affect how the body reacts to the drug itself
Retatrutide, a groundbreaking medication, has emerged as a transformative tool that offers hope for individuals struggling with weight management and diabetes
US$ 22.68
US$ 27.69
US$ 21.11
US$ 26.79
